# Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris

> **NCT01320033** · PHASE2 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 662 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** CD2475/101 40 mg
- **DRUG:** Doxycycline 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01320033
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-29
- **Primary completion:** 2012-01-03
- **Final completion:** 2012-01-03
- **Target enrollment:** 662 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01320033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01320033, "Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01320033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*